Switch theme
Sign up to access all valuation multiples
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
1996
112
LTM Revenue $5.5M
LTM EBITDA -$45.2M
$92.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioInvent International has a last 12-month revenue of $5.5M and a last 12-month EBITDA of -$45.2M.
In the most recent fiscal year, BioInvent International achieved revenue of $4.4M and an EBITDA of -$41.5M.
BioInvent International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioInvent International valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $7.1M | $4.4M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$31.1M | -$41.5M | XXX | XXX | XXX |
| EBITDA Margin | -438% | -934% | XXX | XXX | XXX |
| Net Profit | -$4.2M | -$32.8M | XXX | XXX | XXX |
| Net Margin | -59% | -739% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BioInvent International's stock price is SEK 27 (or $3).
BioInvent International has current market cap of SEK 1.8B (or $177M), and EV of SEK 934M (or $92.7M).
See BioInvent International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $92.7M | $177M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BioInvent International has market cap of $177M and EV of $92.7M.
BioInvent International's trades at 16.9x LTM EV/Revenue multiple, and -2.1x LTM EBITDA.
Analysts estimate BioInvent International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BioInvent International and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $92.7M | XXX | XXX | XXX |
| EV/Revenue | 20.9x | XXX | XXX | XXX |
| EV/EBITDA | -2.2x | XXX | XXX | XXX |
| P/E | -4.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioInvent International's NTM/LTM revenue growth is 239%
BioInvent International's revenue per employee for the last fiscal year averaged $40K, while opex per employee averaged $0.5M for the same period.
Over next 12 months, BioInvent International's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BioInvent International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BioInvent International and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -37% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -934% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -696% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $40K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 130% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1024% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1155% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioInvent International acquired XXX companies to date.
Last acquisition by BioInvent International was XXXXXXXX, XXXXX XXXXX XXXXXX . BioInvent International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BioInvent International founded? | BioInvent International was founded in 1996. |
| Where is BioInvent International headquartered? | BioInvent International is headquartered in Sweden. |
| How many employees does BioInvent International have? | As of today, BioInvent International has 112 employees. |
| Who is the CEO of BioInvent International? | BioInvent International's CEO is Dr. Martin Welschof, PhD. |
| Is BioInvent International publicy listed? | Yes, BioInvent International is a public company listed on STO. |
| What is the stock symbol of BioInvent International? | BioInvent International trades under BINV ticker. |
| When did BioInvent International go public? | BioInvent International went public in 2001. |
| Who are competitors of BioInvent International? | Similar companies to BioInvent International include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BioInvent International? | BioInvent International's current market cap is $177M |
| What is the current revenue of BioInvent International? | BioInvent International's last 12-month revenue is $5.5M. |
| What is the current EBITDA of BioInvent International? | BioInvent International's last 12-month EBITDA is -$45.2M. |
| What is the current EV/Revenue multiple of BioInvent International? | Current revenue multiple of BioInvent International is 16.9x. |
| What is the current EV/EBITDA multiple of BioInvent International? | Current EBITDA multiple of BioInvent International is -2.1x. |
| What is the current revenue growth of BioInvent International? | BioInvent International revenue growth between 2023 and 2024 was -37%. |
| Is BioInvent International profitable? | Yes, BioInvent International is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
